New CFO onboarding is routine; monitor for future Form 4 filings that would indicate insider buying or selling activity.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 2 $3.89entry
- T+1 · 14d ago +6.68%α +6.38% · $4.15
- T+5 · 8d ago +4.11%α +4.03% · $4.05
- T+11 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
How similar events traded
Executive Summary
Vassiliki Economides filed a Form 3 initial statement of beneficial ownership upon becoming Chief Financial Officer of Adial Pharmaceuticals. The filing discloses a stock option grant for 307,814 shares at a $5.76 exercise price, vesting over four years. This is a routine insider onboarding filing with no material financial impact.
Key Facts
- Vassiliki Economides appointed Chief Financial Officer of Adial Pharmaceuticals, Inc.
- Filing is an initial statement of beneficial ownership (Form 3) under Section 16(a).
- Economides holds a stock option to purchase 307,814 shares at $5.76 per share.
- Option vests 25% on first anniversary of grant date (August 19, 2026), then 36 equal monthly installments.
- Option expires on August 19, 2036.
- Power of Attorney filed as Exhibit 24 authorizing Matt Davidson and Cary Claiborne to file Section 16 reports.
Financial Impact
Stock option for 307,814 shares at $5.76 strike price; no immediate cash transaction or dilution impact.
Risk Factors
- No material risks identified; this is a standard insider reporting filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001213900-26-114575 |
| Document: 0001213900-26-114575-index-headers.html | 0001213900-26-114575 |
| Document: 0001213900-26-114575-index.html | 0001213900-26-114575 |
| Document: 0001213900-26-114575.txt | 0001213900-26-114575 |
Track record
23 reports on ADIL
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +138.93% at T+60 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 12, 20265d ago Press Release Neutral 4/10 No price data
- Oct 30, 202617d ago 3 Neutral 2/10 Entry $3.89 settles Jan 29
- Oct 30, 202617d ago 3 Neutral 2/10 Viewing Entry $3.89 settles Jan 29
- Oct 28, 202620d ago 8-K Neutral 5/10 Entry $4.88 settles Jan 27
- Oct 28, 202620d ago Press Release Neutral 5/10 Entry $4.88 settles Jan 27
- Oct 27, 202621d ago EFFECT Bearish 6/10 Entry $3.71 settles Jan 25
- Oct 20, 202627d ago 10-Q/A Bearish 7/10 Entry $4.11 settles Jan 19
- Oct 20, 202627d ago S-3/A Bearish 7/10 Entry $4.11 settles Jan 19
- Oct 16, 20264w ago DEFA14A Bearish 5/10 Entry $3.62 settles Jan 14
- Oct 16, 20264w ago 8-K Bearish 5/10 Entry $3.62 settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers